CA2279492A1 - Tolerance immunologique aux epitopes du hiv - Google Patents

Tolerance immunologique aux epitopes du hiv Download PDF

Info

Publication number
CA2279492A1
CA2279492A1 CA002279492A CA2279492A CA2279492A1 CA 2279492 A1 CA2279492 A1 CA 2279492A1 CA 002279492 A CA002279492 A CA 002279492A CA 2279492 A CA2279492 A CA 2279492A CA 2279492 A1 CA2279492 A1 CA 2279492A1
Authority
CA
Canada
Prior art keywords
seq
cells
epitopes
cell
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002279492A
Other languages
English (en)
Inventor
David Scott
Elias Zambidis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
American National Red Cross
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2279492A1 publication Critical patent/CA2279492A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/162—HIV-1, HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des protéines d'immunoglobuline de fusion (fIg) comprenant un ou plusieurs épitopes hétérologues associés à des maladies pour lesquelles la réponse immunitaire est négative, lesdites protéines étant utiles pour induire une tolérance auxdits épitopes. Les épitopes gp120 du HIV-1 associés à l'intérieur d'un cadre à une chaîne lourde (H) d'Ig sont des produits de synthèse utiles pour induire une tolérance au HIV, spécifique aux épitopes. Le traitement d'un sujet avec ce type de produit de synthèse, ou bien avec des cellules lymphoïdes ou hématopoïétiques exprimant ou sécrétant ces molécules fIg, induit une tolérance immunologique spécifique aux épitopes considérés. En empêchant la production d'anticorps dirigés contre les épitopes gp120 déterminés, cette tolérance peut prévenir ou inhiber l'apoptose de "voisinage" sur les cellules T hôtes non infectées ayant effectué une liaison, à leurs molécules CD4 de surface, avec la protéine gp 120 du HIV et subissant ensuite une réticulation sous l'effet d'anticorps parasites anti-gp120. Cela donne pour les cellules T en question une amorce à l'apoptose, en présence des antigènes qui les activent. On utilise de préférence les épitopes gp120 correspondant à des épitopes de lymphocites B non neutralisants ou certains épitopes de lymphocytes T auxiliaires pour élaborer les molécules fIg. Outre les chaînes H de fIg et les molécules d'Ig complètes, l'invention concerne l'ADN codant les chaînes H en question et les cellules transformées par ce type d'ADN.
CA002279492A 1997-02-13 1998-02-13 Tolerance immunologique aux epitopes du hiv Abandoned CA2279492A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4058197P 1997-02-13 1997-02-13
US60/040,581 1997-02-13
PCT/US1998/002766 WO1998036087A1 (fr) 1997-02-13 1998-02-13 Tolerance immunologique aux epitopes du hiv

Publications (1)

Publication Number Publication Date
CA2279492A1 true CA2279492A1 (fr) 1998-08-20

Family

ID=21911760

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002279492A Abandoned CA2279492A1 (fr) 1997-02-13 1998-02-13 Tolerance immunologique aux epitopes du hiv

Country Status (3)

Country Link
EP (1) EP0973933A1 (fr)
CA (1) CA2279492A1 (fr)
WO (1) WO1998036087A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115262B1 (en) 1999-03-16 2006-10-03 The United States Of America As Represented By The Department Of Health And Human Services Chimeric protein for prevention and treatment of HIV infection
GB9926084D0 (en) * 1999-11-03 2000-01-12 King S College London Recombinant fusion molecules
EP2258712A3 (fr) 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions et procédés permettant d'initier ou d'ameliorer les réponses des cellules T limitées par le complexe majeur d 'histocompatibilité de classe I ou II et un anticorps au moyen de motifs d'ARN non codants immunomodulateurs
CA2562385A1 (fr) * 2004-04-09 2005-10-20 University Of Manitoba Identification de la sequence precise d'acides amines de l'epitope identifie par l'anticorps monoclonal igg1b12 puissant de neutralisation anti-vih 1 humain
WO2007022477A2 (fr) * 2005-08-17 2007-02-22 Multicell Immunotherapeutics, Inc. Méthodes et compositions pour produire et contrôler le profil effecteur de lymphocytes t par chargement et activation simultanés de sous-ensembles sélectionnés de cellules présentatrices d'antigène
EP1878744A1 (fr) 2006-07-13 2008-01-16 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Epitope-tag pour des récepteurs de cellules T exprimés en surface, leurs utilisations et méthode de selection de cellules hôtes les exprimant
US10246505B2 (en) 2013-11-25 2019-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors to control HIV infection
CA2981509A1 (fr) 2015-03-30 2016-10-06 The Board Of Regents Of The Nevada System Of Higher Educ. On Behalf Of The University Of Nevada, La Compositions comprenant des talen et methodes de traitement du vih
WO2016196249A1 (fr) 2015-05-29 2016-12-08 University Of Utah Research Foundation Peptides recombinants de type élastine à tolérance immunitaire et sans tolérance immunitaire et procédés d'utilisation
WO2016207782A1 (fr) * 2015-06-22 2016-12-29 STRELNIKOV, Evgeny Oligopeptides synthétiques immunogènes pour un vaccin contre le vih
KR20230007557A (ko) 2017-09-22 2023-01-12 카이트 파마 인코포레이티드 키메라 폴리펩티드 및 그의 용도
US11198722B2 (en) 2017-10-06 2021-12-14 University Of Utah Research Foundation Immune tolerant elastin-like peptide tetramer guided nanoparticles and methods of use
CN113621033A (zh) * 2019-11-08 2021-11-09 贵州医科大学 一种具有seq id no.3序列的多肽以及具有强adcc效应的抗体和应用

Also Published As

Publication number Publication date
EP0973933A1 (fr) 2000-01-26
WO1998036087A1 (fr) 1998-08-20

Similar Documents

Publication Publication Date Title
JP4214173B2 (ja) 寛容原性融合タンパク質による寛容性の誘発
Crowley et al. Mind the gap: how interspecies variability in IgG and its receptors may complicate comparisons of human and non-human primate effector function
US8188232B1 (en) Compositions and methods for modulating lymphocyte activity
Lanzavecchia Identifying strategies for immune intervention
US7141656B2 (en) MHC complexes and uses thereof
WO1992007574A1 (fr) Glycoproteines associees a des immunoglobulines a liaison membranaire et utilisees comme cibles anticorpales sur des cellules b
CA2279492A1 (fr) Tolerance immunologique aux epitopes du hiv
US20110008332A1 (en) Combination Therapy to Treat Persistent Viral Infections
KR20190131061A (ko) Al 아밀로이드증 치료를 위한 cs1 표적화된 키메라 항원 수용체-변형된 t 세포
CA3184802A1 (fr) Polypeptides du coronavirus 2 associe au syndrome respiratoire aigu severe (sars-cov-2) et leurs utilisations a des fins vaccinales
EP1465928B1 (fr) Anticorps anti-idiotypique induisant des anticorps neutralisant le vih-1
Rivailler et al. Enhanced MHC class II‐restricted presentation of measles virus (MV) hemagglutinin in transgenic mice expressing human MV receptor CD46
AU2003299925B2 (en) KIM-1 antagonists and use to modulate immune system
WO1995029700A1 (fr) Vaccin de synthese protegeant contre l'infection par le vih
Ivanova et al. Targeting of influenza viral epitopes to antigen-presenting cells by genetically engineered chimeric molecules in a humanized NOD SCID Gamma Transfer Model
US7011833B1 (en) Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent
Kang et al. An ongoing immune response to HIV envelope gp120 in human CD4‐transgenic mice contributes to T cell decline upon intravenous administration of gp120
Cassatt et al. Immunization with soluble murine CD4 induces an anti-self antibody response without causing impairment of immune function.
US20170072032A1 (en) Prenatal therapy to induce immune tolerance
Bartnes et al. Native IgG2ab is barely antigenic to major histocompatibility complexclass II‐restricted T cells owing to inefficient internalization by professionalantigen‐presenting cells
KR20230058081A (ko) 인간 IgG1의 변형된 FC 영역과 적어도 하나의 이종 항원을 포함하는 폴리펩티드를 암호화하는 핵산
CN116457009A (zh) 编码包含人IgG1的经修饰的Fc区和至少一种异源抗原的多肽的核酸
Getahun Antibody Feedback Regulation: From Epitope Masking to T Helper Cell Activation
Loci et al. Efficient Isolation of Novel Human
AU2004201321A1 (en) Compositions and methods for treating viral infections

Legal Events

Date Code Title Description
FZDE Discontinued